Who are we ?
Inovpain FHU project offers a unique opportunity to build strong and synergistic collaborations and federate clinical practice, research and teaching activities in a comprehensive program. Inovpain is centered on refractory chronic pains, but mainly focused on neuropathic pain and chronic daily headache.
The project is structured around 6 complementary Work Packages (WP) conducted in parallel . Tight collaboration between clinicians and researchers is essential for a rapid transfer of new fundamental knowledge into clinical practice and personalized healthcare, and to stimulate research from clinical questions.
INOVPAIN is based on effective interactions between clinical teams, academic research teams and industrial partners. Several scientific and health care platforms are involved as well. Altogether, the INOVPAIN project will propose a multidisciplinary, synergistic and regionally organized network focusing on refractory chronic pains.
New mechanism causing migraines discovered by FHU team member
Researchers at CNRS, Université Côte d’Azur and Inserm have demonstrated a new mechanism related to the onset of migraine. They found that a genetic mutation induces dysfunction in a protein which inhibits neuronal electrical activity, causing migraines. These results, published in Neuron on December 17, 2018, open a new path for the development of anti-migraine treatments.
FHU INOVPAIN participated in this important event by organizing a special Neuroscience Day at Nice University Hospital presenting medical procédures, new therapeutics and innovations to the public.
FHU members latest publications
- Medioni, J, Pickering, G, Delorme, C, Lansaman, T, Lanteri-Minet, M, Legras, A et al.. [Drug management of cancer-related peripheral neuropathic pain: A systematic review of the literature]. Bull Cancer. 2019; :. doi: 10.1016/j.bulcan.2019.04.009. PubMed PMID:31202559 .
- Mallet, L, Du Montcel, ST, Clair, AH, Arbus, C, Bardinet, E, Baup, N et al.. Long-term effects of subthalamic stimulation in Obsessive-Compulsive Disorder: Follow-up of a randomized controlled trial. Brain Stimul. 2019; :. doi: 10.1016/j.brs.2019.04.004. PubMed PMID:30992192 .
- Humbert, O, Bourg, V, Mondot, L, Gal, J, Bondiau, PY, Fontaine, D et al.. Correction to: 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. Eur. J. Nucl. Med. Mol. Imaging. 2019;46 (7):1581. doi: 10.1007/s00259-019-04321-8. PubMed PMID:30980100 .
- Zanello, M, Meyer, B, Still, M, Goodden, JR, Colle, H, Schichor, C et al.. Surgical resection of cavernous angioma located within eloquent brain areas: International survey of the practical management among 19 specialized centers. Seizure. 2019;69 :31-40. doi: 10.1016/j.seizure.2019.03.022. PubMed PMID:30959423 .
- Zanello, M, Goodden, JR, Colle, H, Wager, M, Hamer, PCW, Smits, A et al.. Predictors of Epileptic Seizures and Ability to Work in Supratentorial Cavernous Angioma Located Within Eloquent Brain Areas. Neurosurgery. 2019; :. doi: 10.1093/neuros/nyz063. PubMed PMID:30924504 .